Events & Presentations Events & Presentations Latest Corporate Presentation March 11, 2021 Checkmate Pharmaceuticals Corporate Overview – March 2021 Past Events Jefferies Virtual Healthcare Conference 2020 Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… Pagination Current page 1 Page 2 Next page next › Last page last »
Events & Presentations Latest Corporate Presentation March 11, 2021 Checkmate Pharmaceuticals Corporate Overview – March 2021 Past Events Jefferies Virtual Healthcare Conference 2020 Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… Pagination Current page 1 Page 2 Next page next › Last page last »
Jefferies Virtual Healthcare Conference 2020 Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB
SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d…
SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen…
ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons…
AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with …
AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu…
ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v…
